KRAS
Showing 1 - 25 of 893
Advanced Solid Tumor Trial in Guangzhou (YL-17231)
Recruiting
- Advanced Solid Tumor
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Oct 5, 2023
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, NSCLC Trial (ELI-002 7P)
Not yet recruiting
- Pancreatic Ductal Adenocarcinoma
- +14 more
- ELI-002 7P
- (no location specified)
Feb 3, 2023
Non Small Cell Lung Cancer Metastatic, Brain Metastases, Adult, KRAS G12C Trial (JDQ443)
Not yet recruiting
- Non Small Cell Lung Cancer Metastatic
- +2 more
- (no location specified)
Aug 11, 2023
Advanced or Metastatic Solid Tumor, KRAS G12C Mutation Trial in Changsha (BEBT-607Tablets)
Recruiting
- Advanced or Metastatic Solid Tumor
- KRAS G12C Mutation
-
Changsha, Hunan, ChinaXiangya Hospital of Central South University
Nov 2, 2023
KRAS P.G12C, Pancreatic Cancer Trial in Beijing (JAB-21822)
Not yet recruiting
- KRAS P.G12C
- Pancreatic Cancer
-
Beijing, Beijing, China
- +1 more
Aug 18, 2023
Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V Trial in Beijing (KRAS-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)
Recruiting
- Solid Tumor, Adult
- +4 more
- KRAS-EphA-2-CAR-DC
- +3 more
-
Beijing, Beijing, ChinaBiotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022
Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation Trial (Onvansertib, FOLFIRI, Bevacizumab)
Not yet recruiting
- Metastatic Colorectal Cancer
- +2 more
- Onvansertib
- +3 more
- (no location specified)
Oct 24, 2023
Cholangiocarcinoma Trial (GNS561 + Trametinib)
Not yet recruiting
- Cholangiocarcinoma
- GNS561 + Trametinib
- (no location specified)
May 22, 2023
Solid Tumor, KRAS Mutation-Related Tumors Trial in Washington (NEROFE, Doxorubicin)
Recruiting
- Solid Tumor
- KRAS Mutation-Related Tumors
-
Washington, District of ColumbiaGeorgetown Lombardi Comprehensive Cancer Center
Jan 23, 2023
Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)
Not yet recruiting
- Pancreatic Ductal Adenocarcinoma
- Refractory Non-Small Cell Lung Cancer
- Daratumumab
- +2 more
-
Washington, District of ColumbiaGeorgetown Lombardi Comprehensive Cancer Center
Sep 1, 2023
NSCLC, KRAS Mutation-Related Tumors Trial in Philadelphia (Binimetinib Pill, Hydroxychloroquine Pill)
Recruiting
- Non-Small Cell Lung Cancer
- KRAS Mutation-Related Tumors
- Binimetinib Pill
- Hydroxychloroquine Pill
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Sep 30, 2022
Efficacy Trial in Seoul (Oral sotorasib + IV Panitumumab)
Active, not recruiting
- Efficacy
- Oral sotorasib + IV Panitumumab
-
Seoul, Korea, Republic ofKorea University Anam Hospital
Aug 14, 2023
Advanced Solid Tumor Trial in Beijing (YK0901 cells)
Not yet recruiting
- Advanced Solid Tumor
- YK0901 cells
-
Beijing, ChinaDepartment of GI Oncology, Peking University Cancer Hospital
Jun 27, 2023
Each Codon-specific KRAS Mutation in Colorectal Cancer
Completed
- Colorectal Cancer
- Mutation
-
Seongnam-si, Gyeonggi-do, Korea, Republic ofSeoul National University Bundang Hospital
Dec 10, 2022
Advanced Cancer, Metastatic Cancer, Malignant Tumor of Lung Trial in Santa Rosa (Adagrasib)
Recruiting
- Advanced Cancer
- +2 more
-
Santa Rosa, CaliforniaProvidence Medical Foundation
May 2, 2023
NSCLC Trial in Baltimore (Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides
-
Baltimore, MarylandJohns Hopkins University
Jun 16, 2022
Solid Tumors, KRAS Mutation Trial in Chiba, Kashiwa, Tokyo, Chuo-ku, Tokyo, Koto-ku (BI 3011441)
Completed
- Solid Tumors, KRAS Mutation
- BI 3011441
-
Chiba, Kashiwa, Japan
- +2 more
Nov 11, 2022
KRAS G12V Mutant Advanced Epithelial Cancers Trial (Cyclophosphamide, Gemcitabine, Pembrolizumab)
Available
- KRAS G12V Mutant Advanced Epithelial Cancers
- Cyclophosphamide
- +3 more
- (no location specified)
May 19, 2022